Find Senicapoc manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 289656-45-7, 2,2-bis(4-fluorophenyl)-2-phenylacetamide, Ica-17043, Senicapoc (usan), Senicapoc [usan], Ts6g201a6q
Molecular Formula
C20H15F2NO
Molecular Weight
323.3  g/mol
InChI Key
SCTZUZTYRMOMKT-UHFFFAOYSA-N
FDA UNII
TS6G201A6Q

Senicapoc
Senicapoc is an orally bioavailable inhibitor of the calcium-activated potassium channel KCa3.1 (Gardos channel; KCNN4; IK-1; SK4), with potential anti-inflammatory and immunomodulatory activities. Upon oral administration, senicapoc targets, binds to and inhibits KCa3.1. KCa3.1 regulates membrane potential and calcium signaling in a variety of cells including erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium, epithelia, and proliferating vascular smooth muscle cells and fibroblasts. The inhibition of KCa3.1 may prevent erythrocyte dehydration in sickle cell disease, reduce fluid secretion, fluid retention and inflammation in the lungs in acute respiratory distress syndrome (ARDS), and reduce inflammation and immune responses in various other diseases such as neuroinflammation in Alzheimer's disease. Senicapoc exhibits good brain penetration.
1 2D Structure

Senicapoc

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2,2-bis(4-fluorophenyl)-2-phenylacetamide
2.1.2 InChI
InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
2.1.3 InChI Key
SCTZUZTYRMOMKT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
2.2 Other Identifiers
2.2.1 UNII
TS6G201A6Q
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bis(4-fluorophenyl)phenylacetamide

2. Ica 17043

3. Ica-17043

4. Ica17043

2.3.2 Depositor-Supplied Synonyms

1. 289656-45-7

2. 2,2-bis(4-fluorophenyl)-2-phenylacetamide

3. Ica-17043

4. Senicapoc (usan)

5. Senicapoc [usan]

6. Ts6g201a6q

7. Pf-05416266

8. Benzeneacetamide, 4-fluoro-alpha-(4-fluorophenyl)-alpha-phenyl-

9. Bis(4-fluorophenyl)phenylacetamide

10. Senicapoc [usan:inn]

11. Ica 17043

12. Unii-ts6g201a6q

13. 2,2-bis(4-fluorophenyl)-2-phenyl-acetamide

14. 4-fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide

15. Senicapoc [inn]

16. Senicapoc [mart.]

17. Senicapoc [who-dd]

18. Chembl405821

19. Gtpl2331

20. Schembl1443805

21. Amy2744

22. Dtxsid60276906

23. Hms3741e13

24. Act06676

25. Bcp14507

26. Zinc3816408

27. Bbl102413

28. Bdbm50371391

29. Mfcd09027349

30. Stl556215

31. Akos007930800

32. Cs-0294

33. Db06280

34. 4-methyl-1h-pyrrole-2-carboxylic?acid

35. Hy-50694

36. Ms-20434

37. Db-003217

38. Ft-0660387

39. 2,2-bis(4-fluorophenyl)-2-phenyl-ethanamide

40. C74487

41. D06640

42. 656f457

43. A822267

44. A904983

45. Au-004/43508060

46. Q7450628

47. 4-fluoro-a-(4-fluorophenyl)-a-phenyl-benzeneacetamide

2.4 Create Date
2005-08-09
3 Chemical and Physical Properties
Molecular Weight 323.3 g/mol
Molecular Formula C20H15F2NO
XLogP34.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count3
Rotatable Bond Count4
Exact Mass323.11217043 g/mol
Monoisotopic Mass323.11217043 g/mol
Topological Polar Surface Area43.1 Ų
Heavy Atom Count24
Formal Charge0
Complexity397
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in anemia (sickle cell) and asthma.


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty